Arnoult AC, Pernod G, Genty C, Galanaud JP, Colonna M, Sevestre MA, Bosson JL. Low incidence of cancer after venous thromboembolism: An update from the French OPTIMEV Cohort.
ACTA ACUST UNITED AC 2016;
41:169-75. [PMID:
27080824 DOI:
10.1016/j.jmv.2016.03.001]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Accepted: 02/22/2016] [Indexed: 11/29/2022]
Abstract
BACKGROUND
Recent studies have shown lower rates of cancer following venous thromboembolism (VTE) than previously described.
OBJECTIVES
To reassess the risk of cancer in patients with clinical symptoms of VTE with or without confirmed VTE.
PATIENTS
We used data from OPTIMEV, a French prospective multicenter observational study of patients presenting to hospital and community vascular medicine specialists with suspected VTE. Patients with confirmed VTE (1565) and matched controls without VTE (1847) were followed for 3 years (2006-2009). The main outcome was occurrence of cancer at 3 years, and death was a censoring event.
RESULTS
A total of 5.0% [4.0-6.3] of patients with VTE and 3.8% [3.0-4.9] without VTE developed cancer during follow-up. The adjusted hazard ratio (HR) was 1.2 [0.9-1.8] for patients with confirmed VTE (P=0.22). The overall standardized incidence ratio (SIR) was 1.4 [1.1-1.6] for our population, VTE+ and VTE-, compared with the general population, statistically significant (P<0.05).
CONCLUSIONS
We found a lower occurrence of cancer after VTE than previously described, with no significant difference between patients whether VTE was confirmed or not. Our results (low incidence and no difference between patients VTE+ or VTE-) provide no argument in favor of an extensive screening for cancer in case of VTE.
Collapse